{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:05:23Z","timestamp":1776492323387,"version":"3.51.2"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Pediatric Cardiology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ppedcard.2021.101460","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:52:45Z","timestamp":1635900765000},"page":"101460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Genetic correction strategies for Duchenne muscular dystrophy and their impact on the heart"],"prefix":"10.1016","volume":"63","author":[{"given":"Jamie R.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"McNally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ppedcard.2021.101460_bb0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.ppedcard.2021.101460_bb0010","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","article-title":"A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy","volume":"24","author":"Mah","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.ppedcard.2021.101460_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 2","key":"10.1016\/j.ppedcard.2021.101460_bb0020","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1542\/peds.2018-0333I","article-title":"Cardiac management of the patient with Duchenne muscular dystrophy","volume":"142","author":"Buddhe","year":"2018","journal-title":"Pediatrics"},{"issue":"18","key":"10.1016\/j.ppedcard.2021.101460_bb0025","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1161\/CIRCULATIONAHA.114.015151","article-title":"Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy","volume":"131","author":"McNally","year":"2015","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.ppedcard.2021.101460_bb0030","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","article-title":"Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"Griggs","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ppedcard.2021.101460_bb0035","first-page":"CD003725","article-title":"Glucocorticoid corticosteroids for duchenne muscular dystrophy","author":"Manzur","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.ppedcard.2021.101460_bb0040","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1177\/1060028019900500","article-title":"A review of deflazacort for patients with Duchenne muscular dystrophy","volume":"54","author":"Bylo","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.ppedcard.2021.101460_bb0045","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ppedcard.2021.101460_bb0050","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The dystrophin complex: structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr Physiol"},{"issue":"12","key":"10.1016\/j.ppedcard.2021.101460_bb0055","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/humu.21114","article-title":"United Dystrophinopathy Project, R.B. Weiss, Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort","volume":"30","author":"Flanigan","year":"2009","journal-title":"Hum Mutat"},{"issue":"28","key":"10.1016\/j.ppedcard.2021.101460_bb0060","doi-asserted-by":"crossref","first-page":"16456","DOI":"10.1073\/pnas.1910456117","article-title":"Premature termination codons in the DMD gene cause reduced local mRNA synthesis","volume":"117","author":"Garcia-Rodriguez","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11\u201312","key":"10.1016\/j.ppedcard.2021.101460_bb0065","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.nmd.2007.07.005","article-title":"Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human","volume":"17","author":"Neri","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"10.1016\/j.ppedcard.2021.101460_bb0070","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1089\/hum.2016.041","article-title":"Dystrophin threshold level necessary for normalization of neuronal nitric oxide synthase, inducible nitric oxide synthase, and ryanodine receptor-calcium Release Channel type 1 nitrosylation in Golden retriever muscular dystrophy dystrophinopathy","volume":"27","author":"Gentil","year":"2016","journal-title":"Hum Gene Ther"},{"issue":"15","key":"10.1016\/j.ppedcard.2021.101460_bb0075","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","article-title":"How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse","volume":"24","author":"Godfrey","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1016\/j.ppedcard.2021.101460_bb0080","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1172\/JCI32686","article-title":"Torn apart: membrane rupture in muscular dystrophies and associated cardiomyopathies","volume":"117","author":"Lammerding","year":"2007","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.ppedcard.2021.101460_bb0085","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1172\/JCI136873","article-title":"Correction of muscular dystrophies by CRISPR gene editing","volume":"130","author":"Chemello","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ppedcard.2021.101460_bb0090","series-title":"Toward the correction of muscular dystrophy by gene editing","author":"Olson","year":"2021"},{"key":"10.1016\/j.ppedcard.2021.101460_bb0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-med-081117-010451","article-title":"CRISPR correction of duchenne muscular dystrophy","volume":"70","author":"Min","year":"2019","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.ppedcard.2021.101460_bb0100","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum Mutat"},{"issue":"3","key":"10.1016\/j.ppedcard.2021.101460_bb0105","first-page":"1202","article-title":"Antisense oligonucleotides for the treatment of cardiomyopathy in Duchenne muscular dystrophy","volume":"11","author":"Nguyen","year":"2019","journal-title":"Am J Transl Res"},{"issue":"1","key":"10.1016\/j.ppedcard.2021.101460_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther"},{"issue":"26","key":"10.1016\/j.ppedcard.2021.101460_bb0115","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015858","article-title":"Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy","volume":"98","author":"Alfano","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ppedcard.2021.101460_bb0120","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.ppedcard.2021.101460_bb0125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.ppedcard.2021.101460_bb0130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: first approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"issue":"21","key":"10.1016\/j.ppedcard.2021.101460_bb0135","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ppedcard.2021.101460_bb0140","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.ppedcard.2021.101460_bb0145","doi-asserted-by":"crossref","first-page":"545","DOI":"10.15252\/emmm.201607199","article-title":"Delivery is key: lessons learnt from developing splice-switching antisense therapies","volume":"9","author":"Godfrey","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"17","key":"10.1016\/j.ppedcard.2021.101460_bb0150","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/hmg\/ddm158","article-title":"Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain","volume":"16","author":"Banks","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1016\/j.ppedcard.2021.101460_bb0155","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146511","article-title":"Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model","volume":"6","author":"Howard","year":"2021","journal-title":"JCI Insight"},{"issue":"20","key":"10.1016\/j.ppedcard.2021.101460_bb0160","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1093\/hmg\/ddv310","article-title":"Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus","volume":"24","author":"Yue","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"6254","key":"10.1016\/j.ppedcard.2021.101460_bb0165","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ppedcard.2021.101460_bb0170","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.ppedcard.2021.101460_bb0175","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1085","article-title":"Systemic delivery of genes to striated muscles using adeno-associated viral vectors","volume":"10","author":"Gregorevic","year":"2004","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ppedcard.2021.101460_bb0180","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/mt.2008.28","article-title":"Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice","volume":"16","author":"Gregorevic","year":"2008","journal-title":"Mol Ther"},{"issue":"13","key":"10.1016\/j.ppedcard.2021.101460_bb0185","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/01.CIR.0000089371.11664.27","article-title":"Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart","volume":"108","author":"Yue","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ppedcard.2021.101460_bb0190","doi-asserted-by":"crossref","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.ppedcard.2021.101460_bb0195","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.Micro-dystrophin in children with duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ppedcard.2021.101460_bb0200","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.31851","article-title":"Assessment of rAAVrh. 74.MHCK7.Micro-dystrophin gene therapy using magnetic resonance imaging in children with duchenne muscular dystrophy","volume":"4","author":"Willcocks","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.ppedcard.2021.101460_bb0205","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13311-018-00687-z","article-title":"Emerging strategies in the treatment of Duchenne muscular dystrophy","volume":"15","author":"Shieh","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ppedcard.2021.101460_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2018.03.004","article-title":"Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in duchenne muscular dystrophy patients","volume":"342","author":"Leborgne","year":"2019","journal-title":"Cell Immunol"},{"issue":"9869","key":"10.1016\/j.ppedcard.2021.101460_bb0215","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(12)61897-2","article-title":"Muscular dystrophies","volume":"381","author":"Mercuri","year":"2013","journal-title":"Lancet"},{"issue":"7794","key":"10.1016\/j.ppedcard.2021.101460_bb0220","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ppedcard.2021.101460_bb0225","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-018-04252-2","article-title":"The CRISPR tool kit for genome editing and beyond","volume":"9","author":"Adli","year":"2018","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ppedcard.2021.101460_bb0230","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"issue":"6271","key":"10.1016\/j.ppedcard.2021.101460_bb0235","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"issue":"6271","key":"10.1016\/j.ppedcard.2021.101460_bb0240","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"issue":"6271","key":"10.1016\/j.ppedcard.2021.101460_bb0245","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ppedcard.2021.101460_bb0250","doi-asserted-by":"crossref","first-page":"14454","DOI":"10.1038\/ncomms14454","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for duchenne muscular dystrophy","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ppedcard.2021.101460_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1602814","article-title":"CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice","volume":"3","author":"Zhang","year":"2017","journal-title":"Sci Adv"},{"issue":"9","key":"10.1016\/j.ppedcard.2021.101460_bb0260","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ymthe.2020.05.024","article-title":"Correction of three prominent mutations in mouse and human models of duchenne muscular dystrophy by single-cut genome editing","volume":"28","author":"Min","year":"2020","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.ppedcard.2021.101460_bb0265","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav4324","article-title":"CRISPR-Cas9 corrects duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells","volume":"5","author":"Min","year":"2019","journal-title":"Sci Adv"},{"issue":"6410","key":"10.1016\/j.ppedcard.2021.101460_bb0270","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.ppedcard.2021.101460_bb0275","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg4910","article-title":"Precise correction of duchenne muscular dystrophy exon deletion mutations by base and prime editing","volume":"7","author":"Chemello","year":"2021","journal-title":"Sci Adv"},{"issue":"2","key":"10.1016\/j.ppedcard.2021.101460_bb0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nmeth.3733","article-title":"Editing the epigenome: technologies for programmable transcription and epigenetic modulation","volume":"13","author":"Thakore","year":"2016","journal-title":"Nat Methods"},{"issue":"6424","key":"10.1016\/j.ppedcard.2021.101460_bb0285","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau0629","article-title":"CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency","volume":"363","author":"Matharu","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ppedcard.2021.101460_bb0290","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.omtn.2019.04.015","article-title":"Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa","volume":"16","author":"Lau","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"10.1016\/j.ppedcard.2021.101460_bb0295","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41593-017-0060-6","article-title":"In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice","volume":"21","author":"Zhou","year":"2018","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.ppedcard.2021.101460_bb0300","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCRESAHA.118.314522","article-title":"CRISPR-mediated activation of endogenous gene expression in the postnatal heart","volume":"126","author":"Schoger","year":"2020","journal-title":"Circ Res"},{"issue":"7767","key":"10.1016\/j.ppedcard.2021.101460_bb0305","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-019-1430-x","article-title":"A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene","volume":"572","author":"Kemaladewi","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ppedcard.2021.101460_bb0310","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajhg.2015.11.012","article-title":"Spell checking nature: versatility of CRISPR\/Cas9 for developing treatments for inherited disorders","volume":"98","author":"Wojtal","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"7853","key":"10.1016\/j.ppedcard.2021.101460_bb0315","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41586-021-03191-1","article-title":"The NIH somatic cell genome editing program","volume":"592","author":"Saha","year":"2021","journal-title":"Nature"},{"issue":"7831","key":"10.1016\/j.ppedcard.2021.101460_bb0320","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41586-020-2817-4","article-title":"Strategic vision for improving human health at the forefront of genomics","volume":"586","author":"Green","year":"2020","journal-title":"Nature"}],"container-title":["Progress in Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1058981321001405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1058981321001405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:04:03Z","timestamp":1761008643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1058981321001405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":64,"alternative-id":["S1058981321001405"],"URL":"https:\/\/doi.org\/10.1016\/j.ppedcard.2021.101460","relation":{},"ISSN":["1058-9813"],"issn-type":[{"value":"1058-9813","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic correction strategies for Duchenne muscular dystrophy and their impact on the heart","name":"articletitle","label":"Article Title"},{"value":"Progress in Pediatric Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ppedcard.2021.101460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101460"}}